Top 50 Global Pharmaceutical Organization Awards Fourth EDC Study to eResearchTechnology
26 March 2004 - 1:05AM
PR Newswire (US)
Top 50 Global Pharmaceutical Organization Awards Fourth EDC Study
to eResearchTechnology Total Program Level Award Includes More Than
80 Sites Throughout the U.S. PHILADELPHIA, March 25
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a
leading e-research technology and services provider, announced
today that it has been awarded the fourth in a series of electronic
data capture (EDC) studies from a top 50 global pharmaceutical
organization for one of its key drugs in clinical trials. The total
award covers a program of two Phase II and two Phase III studies
that are being conducted at more than 80 research sites distributed
across the U.S. The sponsor is leveraging eRT's enterprise EDC
solution, which provides for rapid study set-up, validation and
deployment, along with the ability to easily aggregate data across
multiple trials for program level analysis. In addition, the
sponsor has elected eRT's site support services, which are designed
to support the process of qualifying and initiating investigator
sites in use of eRT's EDC solution, along with support for site
personnel in use of the EDC system throughout the study process.
"eRT's enterprise EDC capabilities are key to this organization's
ability to deploy four EDC studies in a four-month period," said
Scott Grisanti, senior vice president of business development and
chief marketing officer at eRT. "Further, the roll-out of this EDC
program provides an excellent illustration of eRT's knowledge and
technology transfer program. eRT's enterprise EDC platform has been
successfully implemented within the client's computing
infrastructure, and client staff have been fully trained and are
performing all study configuration activities." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The studies
pertaining to these awards may be canceled by the sponsor at its
sole discretion. As a result, actual results may differ materially
from any financial outlooks stated herein. Further information on
potential factors that could affect the company's financial results
can be found in the company's Reports on Forms 10-K and 10-Q filed
with the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles